FDA Warns Lancome For Gene/Stem-Cell Claims: A Signal To Marketplace?
This article was originally published in The Rose Sheet
L’Oreal/Lancome’s claims for Genifique anti-aging products, among others, identify the products as drugs under food and drug law, according to FDA’s Sept. 7 warning letter. Agency cites claims suggesting the brand’s technology “boosts the activity of genes” and “improve[s] the condition around the stem cells” – language that is not altogether unique in today’s anti-aging cosmeceutical market.
You may also be interested in...
FDA issued close to 30 warning letters to cosmetics firms in 2016 for unapproved drug claims as part of “a project for reviewing product labels and websites for drug claims related to anti-aging.” That initiative may be winding down, if it hasn’t already, but the agency is playing its cards close to its vest going into the new year.
Anti-aging claims in the cosmetics sector show improved compliance with advertising standards overall, but the National Advertising Division remains on the lookout for potential overstatements, particularly as personal-care companies are less inclined to challenge each other than players in other industries.
"The Rose Sheet" makes a case for the theoretical Dollar Anti-Aging Club and why updating the FDCA's "cosmetic" definition as part of broader regulatory reform could be in industry's interest.